Gsk Share Discussion Threads

[jadeticl3] 19/12/2021 16:25

Please help me to understand the difference between marketing authorisation and emergency approval. Thanks.

[alphorn] 19/12/2021 13:28

TM - 'marketing authorization' so not emergency approval. Worth underlining.

[tradermichael] 19/12/2021 08:34

GlaxoSmithKline PLC said Friday that the European Commission has approved its sotrovimab antibody for the early treatment of Covid-19.

The pharmaceutical company and Vir Biotechnology Inc. said the EC, the executive branch of the European Union, has granted marketing authorization.

The product is now approved for the treatment of adults and adolescents at risk of progressing to severe Covid-19.

[supermarky] 17/12/2021 10:29

Thanks. Its always a hard decision for me to sell. Time will tell.

[tradermichael] 17/12/2021 09:25

Nice move!

[supermarky] 17/12/2021 09:24

after buying at 12.20 i have sold out this morning at 16.20. Nice little profit. Looking at the channel up on the daily my thoughts were it was at top of channel and had also been on a lovely run. Leave something for the next guy. Anyway may come in again on any weakness. Moved funds into hsba

[spyder] 17/12/2021 08:17

Here we go again!
Shares up at the open in reflection of good overnight close in US, then quickly fall into negative territory … let’s see how the rest of the day pans out.

[spyder] 16/12/2021 17:17

—> JJ
It looks the US are prioritising the Eli Lilly and Regeneron mABs so that they can use up the pre-ordered stock. It makes sense as it is likely that the Delta variant was still the dominant strain in the US over this period and the Lilly/Regeneron products will work for these cases, thus saving the GSK mAB for when Omicron hits in full force.
—> All
Curious price action in GSK recently. We seem to have reverted to the pattern of down in the morning and up when the US opens which we have seen many times before, but the main curiosity today is a spike in volume at 29m, 3.5x the usual daily volume, I wonder who is selling and who is buying?

[jonjoneil] 16/12/2021 14:07

reason for sudden drop?

'US pauses distribution of GSK/Vir's Covid mAb not due to Omicron, but greater supply of Eli Lilly mAbs'

Typical Glaxo - always the bridesmaid ...

hxxps://endpts.com/us-pauses-distribution-of-gsk-virs-covid-mab-not-due-to-omicron-but-greater-supply-of-eli-lilly-mabs/

[tradermichael] 16/12/2021 13:44

Swing time!

[tradermichael] 16/12/2021 12:05

BofE ups interest rate to 0.25%

[tradermichael] 16/12/2021 09:30

Yes, though it didn't like it above 1400 in the Autumn.

Good new product news since then .....

[spoole5] 16/12/2021 09:25

Doesn't like it above 1600

[tradermichael] 16/12/2021 08:36

Sanofi SA and GlaxoSmithKline PLC said Wednesday that a single booster dose of their Covid-19 vaccine candidate delivered consistently strong immune responses.

Preliminary results from a clinical trial looking at the safety and immunogenicity of the booster shot showed that neutralizing antibodies increased regardless of whether participants had been initially vaccinated with the shot made by AstraZeneca PLC, by Pfizer Inc. and BioNTech SE or by Moderna Inc., the two pharmaceuticals companies said.

[glasgow13] 15/12/2021 14:37

French like to take there time.

[jonjoneil] 15/12/2021 13:23

My guess, reading between the lines, is that there are still delays in recruiting enough people for trials. I believe the blame for the delay in first phase trials was down to Sanofi. But I could be wrong.

[pierre oreilly] 15/12/2021 12:55

The only thing i saw on the timing of phase 3 completion the previous official rns was

'Full results of the Phase 3 study will be released in a peer-reviewed publication as soon as possible.'

I don't think specifying 1q 22 means a delay from that.

I can only think the quotes above are for some delay from a timing mentioned previously to the lastest 2 update rnss.

Anyhow, we can now expect results 1Q 22 (or a delay from there).

Hopefully, we could get mhra emergency approval based on the interim report.

[jonjoneil] 15/12/2021 11:58

(Bloomberg) -- Sanofi and GlaxoSmithKline Plc, the pharma giants that stumbled in the race to develop a Covid-19 shot, said their experimental vaccine works as a booster but suffered yet another delay with the main clinical trial results.

The booster raised the antibody levels of people who’d already received other inoculations such as Pfizer Inc.’s and AstraZeneca Plc’s, the drugmakers said in a statement Wednesday. Yet crucial study results for the underlying vaccine were delayed to the first quarter.

hxxps://www.bnnbloomberg.ca/sanofi-glaxo-covid-shot-works-as-booster-but-stalls-again-1.1696067

[keyno] 15/12/2021 11:35

Apologies PO, I thought you had.

[pierre oreilly] 15/12/2021 11:29

I have not edited my post.

I'm not saying there has been no delay since the program was initiated. I'm saying the timescales before the announcement are exactly the timescales at the announcement and no new delay has been announced.

[keyno] 15/12/2021 11:20

Anyway - investment aside, it looks like we might well have another good vaccine to use against CV19 soon so that's got to be positive news.

[keyno] 15/12/2021 11:14

I recall some months ago they were expecting to announce Phase III results by end of '21.

I think you've edited your post so maybe the above doesn't make sense now, PO.

[pierre oreilly] 15/12/2021 11:11

What delay? There is no delay - it's still on track for phase 3 finishing 1st q 22.

They just reported some preliminary results. Probably hoping the mhra could relax their extremely strict requirements and get emergency approval for the vaccine in advance of the full study results.

[keyno] 15/12/2021 11:06

Tiresome isn't it? But positive news so far.